Sign inJoin waitlistJoin the waitlist

Amir Fathi

Physician · Massachusetts General Hospital

Credentials: · · · · · ·

History

Massachusetts General Hospital
Present

Hematology and Medical Oncology
Johns Hopkins Hospital
2007–2010
Internal Medicine
Massachusetts General Hospital
2004–2007
Yale Univ Sch of Med
2000–2004

Research

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML
New England Journal of Medicine · 2018 · 1,234 citations
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Blood · 2017 · 1,232 citations
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations

Andrew Brunner
72 papers · 20 as a fellow
GH
Gabriela Hobbs
37 papers
PA
Philip Amrein
36 papers
Richard Stone
36 papers
Daniel DeAngelo
23 papers
Karen Ballen
22 papers
Courtney DiNardo
21 papers
EA
Eyal Attar
21 papers
ES
Eytan Stein
21 papers
Jessica Altman
21 papers
Gail Roboz
20 papers
Robert Hasserjian
20 papers

Clinical trials

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML
Principal investigator · Not yet recruiting · Phase 1
Massachusetts General Hospital
2026–2028
Ivosidenib as Post-HSCT Maintenance for AML
Principal investigator · Recruiting · Phase 2
Massachusetts General Hospital
2026–2030
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Principal investigator · Active not recruiting · Phase 2
Massachusetts General Hospital
2021–2028
IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation
Principal investigator · Completed · Phase 1
Massachusetts General Hospital
2019–2023